Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Atara Biotherapeutics Securities Class Action
Business class action

Atara Biotherapeutics Securities Class Action

Analysis based on 58 articles · First reported Apr 01, 2026 · Last updated May 07, 2026

Sentiment
-40
Attention
4
Articles
58
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Atara Biotherapeutics for alleged misleading statements regarding its drug approval prospects and manufacturing issues is likely to negatively impact its stock price and investor confidence. The legal proceedings could result in significant financial liabilities for Atara Biotherapeutics, while Rosen Law Firm stands to gain from a successful outcome.

Biotechnology Legal Services
Event Summary

Rosen Law Firm has filed a class action lawsuit against Atara Biotherapeutics, alleging that the company made false and misleading statements to investors between May 20, 2024, and January 9, 2026. The lawsuit claims that Atara Biotherapeutics overstated the regulatory prospects of its drug tabelecleucel, failing to disclose manufacturing issues and deficiencies in the ALLELE study that made United States — Food and Drug Administration approval unlikely. These issues also allegedly exposed Atara Biotherapeutics to heightened regulatory scrutiny and jeopardized its clinical trials, ultimately impacting its business and financial condition. Rosen Law Firm, with attorneys Philip Kim and Lawrence Rosen, is encouraging investors who purchased Atara Biotherapeutics securities during the specified period to join the class action, with a lead plaintiff deadline of May 22, 2026.

Key Actions
100 Levi & Korsinsky notifies investors of lawsuit Atara Biotherapeutics
100 Robbins LLP filed class action Atara Biotherapeutics
95 Rosen Law Firm filed class action lawsuit Atara Biotherapeutics
91 Atara Biotherapeutics made misleading statements
90 United States — Food and Drug Administration issued Complete Response Letter Atara Biotherapeutics
62 Atara Biotherapeutics submitted Biologics License Application United States — Food and Drug Administration
Entities Involved
stock
Atara Biotherapeutics
Atara Biotherapeutics is the defendant in a class action lawsuit alleging misleading statements regarding its tabelecleucel Biologics License Application and manufacturing issues. This event negatively impacts its stock price and reputation.
Importance 100 Sentiment -45
priv
Rosen Law Firm
Rosen Law Firm is representing investors in a class action lawsuit against Atara Biotherapeutics, seeking compensation for alleged damages.
Importance 90 Sentiment 20
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm initiating the class action securities lawsuit against Atara Biotherapeutics, representing investors who suffered losses.
Importance 80 Sentiment 20
priv
Robbins LLP
Robbins LLP is a law firm that filed a class action lawsuit against Atara Biotherapeutics on behalf of investors who lost money.
Importance 80 Sentiment 50
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration's potential non-approval of tabelecleucel's Biologics License Application due to manufacturing issues is a key factor in the lawsuit against Atara Biotherapeutics.
Importance 50 Sentiment 0
per
Joseph E. Levi
Joseph E. Levi is an attorney at Levi & Korsinsky, serving as a contact for investors interested in the class action lawsuit against Atara Biotherapeutics.
Importance 40 Sentiment 10
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm, involved in the class action lawsuit against Atara Biotherapeutics.
Importance 30 Sentiment 10
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm, which is pursuing a class action lawsuit against Atara Biotherapeutics.
Importance 30 Sentiment 10
per
Aaron Dumas, Jr.
Aaron Dumas, Jr. is an attorney at Robbins LLP, mentioned as a contact for shareholders interested in the class action.
Importance 20 Sentiment 0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Atara Biotherapeutics' securities are traded.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.